Recent studies have centered on the overlap of GLP-1|GIP|glucagon receptor agonist therapies and DA communication. While GCGR activators are commonly employed for managing type 2 diabetes mellitus, their unexpected consequences on motivation circuits, specifically influenced by DA systems, are receiving considerable attention. This article presents